Functional Reserve Estimation of Donor Kidney

February 10, 2015 updated by: Nazarbayev University

Improving of Morphological,Clinical Biochemical and Instrumental Functional Reserve Estimation of Donor Kidney

The purpose of the study:

  • To estimate the role of morphological, clinical, biochemical and imaging studies at stages of kidney transplantation (medical therapy, explantation, preservation, transplantation).
  • To improve the ways of preserving optimal functional parameters of renal transplants.

Study Overview

Detailed Description

Terminal chronic renal failure (ESRD) as a result of almost any chronic kidney disease develops due to progressive loss of nephrons. This state is characterized by a gradual deterioration of the functional abilities of not only the kidneys, but also the whole body. Currently, ESRD is among the first ten causes of mortality .

Transplantation of donor organs is the only radical treatment for various diseases of the terminal, for patients with a fatal prognosis.

Kidney transplantation has allowed not only save lives, but also to return to normal life, tens of thousands of people. Survival of renal transplant recipients is growing.

Despite the progress made in many clinics worldwide in recent years in the field of transplantation, kidney transplantation, does not settle the problem of reperfusion injury and the associated post-transplant dysfunction with the absence of clear indicators of morphological, clinical, biochemical and instrumental methods to assess functional reserve of organs that remain relevant and meaningful.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Astana, Kazakhstan, 010000
        • Republican Scientific Center for Emergency Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • recipients-patients with end-stage renal disease;
  • donor healthy people without absolute contraindications to the kidney transplantation;
  • donor and recipients who are both in the genetic and non-genetic related to each other.
  • obligatory immunological compatibility by HLA-phenotyping provided that the donor and recipient are not relatives with each other;
  • negative result of cross-match between donors and recipients;
  • presence of pre-existing lymphotoxic antibodies in a recipient less than 50%;
  • absence of standard absolute contraindications in a donor and in a recipient for surgeric intervention.

Age is 18-60 years.

Exclusion Criteria:

  • patients with absolute contraindications to surgery: diseases of organs and systems having a threating risk to the life of donor and recipient during and after surgery;
  • immunological incompatibility between donor and recipient;
  • high level of pre-existing lymphotoxic antibodies in a recipient more than 50%, uncorrected by Therapy;
  • donor age is under 18 and over 60 years;
  • incapable persons;
  • absence of a notarized consent form to kidney transplantation;
  • presence of the active phase of viral infection with hepatitis B and C;
  • positive results of blood tests for HIV/AIDS, syphilis;
  • patients with severe concomitant pathology of kidneys, (or) heart and (or)liver.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Kidney transplantation
Kidney transplantation from alive relative donor.
Donor kidney sampling, preservation, transport and transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Reserve Estimation of Donor Kidney
Time Frame: for 12 months

Graft survival is assessed on the following criteria:

  • The duration of the functioning graft
  • Clinical, laboratory and device functioning graft.
  • Morphological and histological study of the stages of transplantation (for withdrawal, before implantation) and the post-transplant period (with the threat of rejection.) Study of the blood recipient: Laboratory tests of blood recipient: biochemical analysis, the composition of the electrolyte, acid-base status, the level of immunosuppressants. Immunological typing for HLA-system. Cross-typing of donor and recipient, the level of pre-existing limfotsitotoksicheskih antibodies in the recipient.Patients survival.
for 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical and Laboratory,Imaging Parameters
Time Frame: From 2 hours to 7 days
  • Intraoperational Macroscopic Description of signs of kidney ischemia: turgor, colour, consistency of transplanted kidney, pulse characteristics of renal artery.
  • Signs of graft rejection: increasing of temperature, blood pressure, the levels of waste products (blood creatinine, blood urea).
From 2 hours to 7 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pre-Operative Patients Health Status: Donor and Recipient
Time Frame: For 1 week
  • Patient-donor health status.
  • Concomitant somatic pathology of a patient-recipient.
  • Time for Kidney transplantation.
For 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gani M Kuttymuratov, Phd, Advisor to the Board Chairman

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2011

Primary Completion (Actual)

September 1, 2011

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

September 17, 2012

First Submitted That Met QC Criteria

September 20, 2012

First Posted (Estimate)

September 21, 2012

Study Record Updates

Last Update Posted (Estimate)

February 11, 2015

Last Update Submitted That Met QC Criteria

February 10, 2015

Last Verified

February 1, 2015

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on End-stage Renal Disease

Clinical Trials on Kidney Transplantation from alive relative donor

3
Subscribe